1. Electroconvulsive Therapy Safety Biomarkers
- Subjects
- electroconvulsive therapy
- Abstract
Objective: The two studies presented utilize neuroimaging data to evaluate potential therapeutic and safety biomarkers in depressed patients receiving Electroconvulsive Therapy (ECT). Method: The first study enrolled 41 depressed subjects receiving ECT from two independent sites and evaluated gamma aminobutyric acid (GABA+) in the anterior cingulate cortex with proton-spectroscopy contrasted with healthy controls and therapeutic and cognitive outcomes. The second study investigated 17 subjects receiving ECT and evaluated ictal theta power during ECT to electric dose measured by E-field modeling, therapeutic and cognitive outcomes. Results: No significant difference was seen in GABA+ in depressed subjects receiving ECT compared to healthy controls and no association was found with therapeutic outcomes; however, change in GABA+ may be related to cognitive outcomes. Ictal theta power was found to be associated with dose (E-field strength) and cognitive outcomes. Conclusion: Both ∆GABA+ and ictal theta power have potential to be ECT safety biomarkers.
- Published
- 2022